vs
National Healthcare Properties, Inc.（NHPAP）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
National Healthcare Properties, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.2倍（$84.5M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -27.0%，领先411.0%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -3.7%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -2.2%）
本公司是一家总部位于英国伦敦的房地产投资企业，核心业务为投资运营基础医疗设施。截至2025年6月，公司在英国和爱尔兰拥有并运营超过500家基础医疗机构，目前在伦敦证券交易所上市，是富时250指数的成分股之一。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
NHPAP vs RIGL — 直观对比
营收规模更大
NHPAP
是对方的1.2倍
$69.8M
营收增速更快
RIGL
高出24.9%
-3.7%
净利率更高
RIGL
高出411.0%
-27.0%
两年增速更快
RIGL
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $84.5M | $69.8M |
| 净利润 | $-22.8M | $268.1M |
| 毛利率 | 36.5% | 91.5% |
| 营业利润率 | -7.8% | 33.2% |
| 净利率 | -27.0% | 384.0% |
| 营收同比 | -3.7% | 21.2% |
| 净利润同比 | -33.9% | 1769.2% |
| 每股收益（稀释后） | $-0.92 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NHPAPRIGL
| Q4 25 | $84.5M | $69.8M | ||
| Q3 25 | $86.0M | $69.5M | ||
| Q2 25 | $85.3M | $101.7M | ||
| Q1 25 | $86.4M | $53.3M | ||
| Q4 24 | $87.7M | $57.6M | ||
| Q3 24 | $88.9M | $55.3M | ||
| Q2 24 | $88.8M | $36.8M | ||
| Q1 24 | $88.3M | $29.5M |
净利润NHPAPRIGL
| Q4 25 | $-22.8M | $268.1M | ||
| Q3 25 | $-12.5M | $27.9M | ||
| Q2 25 | $-20.8M | $59.6M | ||
| Q1 25 | $-1.5M | $11.4M | ||
| Q4 24 | $-17.0M | $14.3M | ||
| Q3 24 | $-40.8M | $12.4M | ||
| Q2 24 | $-116.9M | $-1.0M | ||
| Q1 24 | $-15.6M | $-8.2M |
毛利率NHPAPRIGL
| Q4 25 | 36.5% | 91.5% | ||
| Q3 25 | 37.4% | 93.2% | ||
| Q2 25 | 36.9% | 95.6% | ||
| Q1 25 | 33.4% | 91.7% | ||
| Q4 24 | 37.4% | 89.9% | ||
| Q3 24 | 36.6% | 85.5% | ||
| Q2 24 | 38.1% | 92.4% | ||
| Q1 24 | 37.5% | 93.1% |
营业利润率NHPAPRIGL
| Q4 25 | -7.8% | 33.2% | ||
| Q3 25 | 2.8% | 40.9% | ||
| Q2 25 | -6.5% | 60.1% | ||
| Q1 25 | 15.1% | 23.9% | ||
| Q4 24 | -1.2% | 28.9% | ||
| Q3 24 | -23.5% | 25.4% | ||
| Q2 24 | -113.1% | 1.2% | ||
| Q1 24 | -1.3% | -23.6% |
净利率NHPAPRIGL
| Q4 25 | -27.0% | 384.0% | ||
| Q3 25 | -14.6% | 40.2% | ||
| Q2 25 | -24.4% | 58.6% | ||
| Q1 25 | -1.8% | 21.5% | ||
| Q4 24 | -19.4% | 24.9% | ||
| Q3 24 | -45.8% | 22.5% | ||
| Q2 24 | -131.6% | -2.8% | ||
| Q1 24 | -17.6% | -27.9% |
每股收益（稀释后）NHPAPRIGL
| Q4 25 | $-0.92 | $14.11 | ||
| Q3 25 | $-0.56 | $1.46 | ||
| Q2 25 | $-0.85 | $3.28 | ||
| Q1 25 | $-0.18 | $0.63 | ||
| Q4 24 | $-0.72 | $0.82 | ||
| Q3 24 | $-1.56 | $0.70 | ||
| Q2 24 | $-4.24 | $-0.06 | ||
| Q1 24 | $-0.67 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.6M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $600.1M | $391.5M |
| 总资产 | $1.7B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资NHPAPRIGL
| Q4 25 | $57.6M | $155.0M | ||
| Q3 25 | $47.1M | $137.1M | ||
| Q2 25 | $47.1M | $108.4M | ||
| Q1 25 | $71.4M | $77.1M | ||
| Q4 24 | $21.7M | $77.3M | ||
| Q3 24 | $32.9M | $61.1M | ||
| Q2 24 | $29.5M | $49.1M | ||
| Q1 24 | $28.7M | $49.5M |
总债务NHPAPRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益NHPAPRIGL
| Q4 25 | $600.1M | $391.5M | ||
| Q3 25 | $627.2M | $117.6M | ||
| Q2 25 | $647.0M | $81.9M | ||
| Q1 25 | $674.6M | $18.6M | ||
| Q4 24 | $684.6M | $3.3M | ||
| Q3 24 | $702.6M | $-14.6M | ||
| Q2 24 | $756.7M | $-29.9M | ||
| Q1 24 | $877.7M | $-31.7M |
总资产NHPAPRIGL
| Q4 25 | $1.7B | $513.6M | ||
| Q3 25 | $1.7B | $242.5M | ||
| Q2 25 | $1.8B | $206.7M | ||
| Q1 25 | $1.8B | $176.0M | ||
| Q4 24 | $1.9B | $164.0M | ||
| Q3 24 | $2.0B | $139.4M | ||
| Q2 24 | $2.1B | $128.4M | ||
| Q1 24 | $2.1B | $126.5M |
负债/权益比NHPAPRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流NHPAPRIGL
| Q4 25 | $7.0M | $22.0M | ||
| Q3 25 | $10.2M | $24.0M | ||
| Q2 25 | $8.1M | $30.5M | ||
| Q1 25 | $-21.2M | $-893.0K | ||
| Q4 24 | $-79.8M | $14.5M | ||
| Q3 24 | $-95.2M | $21.7M | ||
| Q2 24 | $6.4M | $302.0K | ||
| Q1 24 | $2.5M | $-5.0M |
现金转化率NHPAPRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NHPAP
| Seniors Housing Communities | $56.3M | 67% |
| Outpatient Medical Facilities | $28.1M | 33% |
RIGL
暂无分部数据
